VACCINEX, INC. Contracts & Agreements
77 Contracts & Agreements
- Business Finance (50 contracts)
- Business Operations (5)
- Human Resources (6)
- Intellectual Property (2)
- Uncategorized (14)
- Form of Amendment and Restatement of the Vaccinex, Inc. Common Stock Purchase Warrant (February 2024, as amended March 2024) (Filed With SEC on May 15, 2024)
- Form of Amendment and Restatement of the Vaccinex, Inc. Common Stock Purchase Warrant (November 2023, as amended March 2024) (Filed With SEC on May 15, 2024)
- Form of Amendment and Restatement of the Vaccinex, Inc. Common Stock Purchase Warrant (October 2023, as amended March 2024) (Filed With SEC on May 15, 2024)
- Form of Common Stock Purchase Warrant for the AGP Transactions, dated March 28, 2024 (Filed With SEC on April 1, 2024)
- Form of Common Stock Purchase Warrant for Private Placement, dated March 28, 2024 (Filed With SEC on April 1, 2024)
- Common Stock Purchase Warrant issued to Alzheimers Drug Discovery Foundation, dated March 29, 2024 (Filed With SEC on April 1, 2024)
- Form of Securities Purchase Agreement for the AGP Transactions, by and between the Company and each purchaser identified on the signature pages thereto, dated as of March 27, 2024 (Filed With SEC on April 1, 2024)
- Form of Securities Purchase Agreement for the Additional Private Placement, by and between the Company and each purchaser identified on the signature pages thereto, dated as of... (Filed With SEC on April 1, 2024)
- Securities Purchase Agreement, by and between the Company and Alzheimers Drug Discovery Foundation, dated as of March 29, 2024 (Filed With SEC on April 1, 2024)
- Registration Rights Agreement, by and between the Company and Alzheimers Drug Discovery Foundation, dated as of March 29, 2024 (Filed With SEC on April 1, 2024)
- Form of Common Warrant (Filed With SEC on February 8, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on February 7, 2024)
- Form of Common Warrant (Filed With SEC on February 7, 2024)
- Securities Purchase Agreement by and between the Company and the Investors, dated as of February 6, 2024 (Filed With SEC on February 7, 2024)
- Registration Rights Agreement by and between the Company and the Investors, dated as of February 7, 2024 (Filed With SEC on February 7, 2024)
- Placement Agency Agreement, dated as of September 28, 2023, by and between Vaccinex, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on October 4, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on October 4, 2023)
- Form of Common Stock Warrant (Filed With SEC on October 4, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on October 4, 2023)
- Form of Placement Agent Agreement (Filed With SEC on September 26, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on September 26, 2023)
- Form of Common Stock Purchase Warrant (Filed With SEC on September 26, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on September 26, 2023)
- Stock Purchase Agreement by and between the Company and the Investors, dated as of September 20, 2023 (Filed With SEC on September 22, 2023)
- Registration Rights Agreement by and between the Company and the Investors, dated as of September 20, 2023 (Filed With SEC on September 22, 2023)
- Stock Purchase Agreement by and between the Company and the Investors, dated as of August 18, 2023 (Filed With SEC on August 22, 2023)
- Registration Rights Agreement by and between the Company and the Investors, dated as of August 18, 2023 (Filed With SEC on August 22, 2023)
- Stock Purchase Agreement, by and between the Company and the Investors (as defined therein), dated as of May 12, 2023 (Filed With SEC on May 15, 2023)
- Stock Purchase Agreement by and between the Company and the Investors (as defined therein), dated as of March 30, 2023 (Filed With SEC on April 3, 2023)
- Stock Purchase Agreement by and between the Company and the Investors (as defined therein), dated as of January 27, 2022, Amendment to Stock Purchase Agreement by and between the... (Filed With SEC on January 31, 2022)
- Registration Rights Agreement by and between the Company and the Investors (as defined therein), dated as of January 31, 2022 (Filed With SEC on January 31, 2022)
- Separation Agreement by and between the Company and Raymond E. Watkins dated December 9, 2020 (Filed With SEC on March 31, 2021)
- 7% Original Issue Discount Senior Convertible Debenture due August 3, 2021 (Filed With SEC on August 14, 2020)
- Registration Rights Agreement, dated August 3, 2020, by and among the Company and 3i, LP (Filed With SEC on August 14, 2020)
- Security Agreement, dated July 31, 2020, by and between the Company and 3i, LP, as Collateral Agent (Filed With SEC on August 14, 2020)
- Form of 7% Original Issue Discount Senior Secured Convertible Debenture due August 3, 2021 (Filed With SEC on July 31, 2020)
- Securities Purchase Agreement, dated July 30, 2020, by and among the Company and the Purchaser (Filed With SEC on July 31, 2020)
- Form of Registration Rights Agreement by and among the Company and the Purchaser (Filed With SEC on July 31, 2020)
- Form of Security Agreement by and between the Company and 3i, LP, as Collateral Agent (Filed With SEC on July 31, 2020)
- Stock Purchase Agreement by and between the Company and Friedberg Global-Macro Hedge Fund, Ltd., dated as of July 9, 2020 (Filed With SEC on July 10, 2020)
- Registration Rights Agreement by and between the Company and Friedberg Global-Macro Hedge Fund, Ltd., dated as of July 10, 2020 (Filed With SEC on July 10, 2020)
- Note by and between the Company and Five Star Bank, dated May 8, 2020 (Filed With SEC on May 14, 2020)
- Registration Rights Agreement by and between the Company and Keystone Capital Partners, LLC, dated March 27, 2020 (Filed With SEC on March 27, 2020)
- Open Market Sale AgreementSM by and between the Company and Jefferies, LLC, dated March 27, 2020 (Filed With SEC on March 27, 2020)
- Purchase Agreement by and between the Company and Keystone Capital Partners, LLC, dated March 27, 2020 (Filed With SEC on March 27, 2020)
- Description of Common Stock (Filed With SEC on March 9, 2020)
- Stock Purchase Agreement by and between the Company and the Investors (as defined therein), dated as of January 21, 2020 (Filed With SEC on January 23, 2020)
- Registration Rights Agreement by and between the Company and the Investors (as defined therein), dated as of January 23, 2020 (Filed With SEC on January 23, 2020)
- Stock Purchase Agreement by and between the Company and the Investors (as defined therein), dated as of July 26, 2019 (Filed With SEC on July 31, 2019)
- Registration Rights Agreement by and between the Company and the Investors (as defined therein), dated as of July 30, 2019 (Filed With SEC on July 31, 2019)
- VX3 Exchange Agreement, dated August 13, 2018, by and among the Company, VX3 Inc., VX3 (DE) LP, FCMI Parent Co., and certain investors listed on Schedule A thereto (Filed With SEC on March 13, 2019)
- Vaccinex, Inc. 2001 Employee Equity Plan (as amended May 25, 2006) (Filed With SEC on August 8, 2018)
- May 15, 2014 Amendment to the Vaccinex, Inc. 2011 Employee Equity Plan (Filed With SEC on August 8, 2018)
- Form of Underwriting Agreement (Filed With SEC on July 23, 2018)
- 2018 Omnibus Incentive Plan (Filed With SEC on July 23, 2018)
- Form of Incentive Stock Option Agreement under 2018 Omnibus Incentive Plan (Filed With SEC on July 23, 2018)
- Form of Non-Qualified Stock Option Agreement under 2018 Omnibus Incentive Plan (Filed With SEC on July 23, 2018)
- Director Compensation Program (Filed With SEC on July 23, 2018)
- Specimen Common Stock Certificate (Filed With SEC on July 9, 2018)
- First Amended and Restated Investor Rights Agreement, dated August 22, 2003, by and among the Company and the parties thereto (Filed With SEC on July 9, 2018)
- 2001 Employee Equity Plan (Filed With SEC on July 9, 2018)
- Form of Stock Option Agreement under 2001 Employee Equity Plan (Filed With SEC on July 9, 2018)
- 2011 Employee Equity Plan (Filed With SEC on July 9, 2018)
- Form of Stock Option Agreement under 2011 Employee Equity Plan (Filed With SEC on July 9, 2018)
- Severance Pay Plan (Filed With SEC on July 9, 2018)
- Form of Indemnification Agreement by and between the Company and each of its directors and officers (Filed With SEC on July 9, 2018)
- Exclusive License Agreement, dated December 29, 1998, by and between the Company and the University of Rochester (Filed With SEC on July 9, 2018)
- GPEx Development and Manufacturing Agreement, dated January 13, 2010, by and between the Company and Catalent Pharma Solutions, LLC (Filed With SEC on July 9, 2018)
- GPEx Derived Cell Line Sale Agreement, dated January 13, 2010, by and between the Company and Catalent Pharma Solutions, LLC (Filed With SEC on July 9, 2018)
- Amended and Restated Exchange Agreement, dated October 24, 2014, by and among the Company and the parties listed therein (Filed With SEC on July 9, 2018)
- Clinical Trial Collaboration and Supply Agreement, dated October 4, 2016, by and between the Company and Ares Trading S.A (Filed With SEC on July 9, 2018)
- License Agreement, dated November 6, 2017, by and between the Company and VX3 (DE) LP (Filed With SEC on July 9, 2018)
- Services Agreement, dated November 6, 2017, by and between the Company and VX3 (DE) LP (Filed With SEC on July 9, 2018)
- Consent and Amendment, dated February 28, 2018, by and among VX3 Inc., FCMI Parent Co., the Company and VX3 (DE) LP (Filed With SEC on July 9, 2018)
- Consent and Amendment, dated May 15, 2018, by and among VX3 Inc., FCMI Parent Co., the Company and VX3 (DE) LP (Filed With SEC on July 9, 2018)
- Consent and Amendment, dated June 12, 2018, by and among VX3, Inc., FCMI Parent Co., the Company and VX3 (DE) LP (Filed With SEC on July 9, 2018)
- Agreement, dated March 16, 2018, by and among the Company, VX3 (DE) LP, VX3 Inc., and each of the other parties on the signature pages thereto (Filed With SEC on July 9, 2018)
